Clene vs Cytomed Therapeutics
Cytomed Therapeutics is the larger business, with $248,384 of revenue in fiscal 2025 against $200,000 for Clene (1.2 times as much). Cytomed Therapeutics grew faster (377.5% against -41.5%). Cytomed Therapeutics kept more of each dollar of sales as profit: a net margin of -1227.1% against -13086.5%.
| Latest fiscal year | CleneCLNN, 2025 | Cytomed TherapeuticsGDTC, 2025 |
|---|---|---|
| Revenue | $200,000 | $248,384 |
| Revenue growth | -41.5% | 377.5% |
| Net income | −$26.2m | −$3.0m |
| Operating margin | — | — |
| Net margin | -13086.5% | -1227.1% |
| Return on equity | — | -52.3% |
| Free cash flow | −$18.6m | −$3.3m |
| Cash | $5.2m | $1.6m |
| Total debt | $17.8m | $318,456 |
| Debt to equity | — | 6.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 79 | — |
| Market value | $47.9m | $10.2m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | — |
| Insider trades, 12 months | 1 buys, 62 sales | 5 buys, 0 sales |